ETFIS Series Trust I (PFFR) NPORT-P Virtus LifeSci Biotech Products ETF (Jul 2023 report)

Schedule of Investments - Virtus LifeSci Biotech Products ETF

July 31, 2023 (unaudited)

Security Description	Shares		Value
COMMON STOCKS - 99.3%
Health Care - 99.3%
2seventy bio, Inc.*(1)		31,965	$	242,614
ACADIA Pharmaceuticals, Inc.*		14,235		416,231
ADMA Biologics, Inc.*		88,335		366,590
Agios Pharmaceuticals, Inc.*(1)		13,355		354,175
Alnylam Pharmaceuticals, Inc.*		1,731		338,237
Amgen, Inc.		1,546		361,996
Amicus Therapeutics, Inc.*		25,836		351,886
Amylyx Pharmaceuticals, Inc.*(1)		13,806		323,751
Apellis Pharmaceuticals, Inc.*		3,730		96,048
Ascendis Pharma A/S (Denmark)*(2)		3,802		342,750
Aurinia Pharmaceuticals, Inc. (Canada)*		34,850		403,563
Axsome Therapeutics, Inc.*(1)		4,247		333,262
BeiGene Ltd. (China)*(1)(2)		1,651		353,677
BioCryst Pharmaceuticals, Inc.*		43,278		319,824
Biogen, Inc.*		1,145		309,368
BioMarin Pharmaceutical, Inc.*		3,640		320,065
BioNTech SE (Germany)*(2)		3,097		337,170
Bluebird Bio, Inc.*(1)		89,022		349,857
Blueprint Medicines Corp.*		5,848		385,968
Bridgebio Pharma, Inc.*		20,345		712,278
Deciphera Pharmaceuticals, Inc.*		24,233		327,630
Enanta Pharmaceuticals, Inc.*		14,438		273,889
Exelixis, Inc.*		18,297		360,634
Gilead Sciences, Inc.		4,408		335,625
Halozyme Therapeutics, Inc.*		10,422		447,729
Harmony Biosciences Holdings, Inc.*		9,609		339,870
Immunocore Holdings PLC (United Kingdom)*(1)(2)		5,949		392,515
ImmunoGen, Inc.*		19,392		345,565
Incyte Corp.*		5,593		356,386
Insmed, Inc.*		17,814		393,511
Intercept Pharmaceuticals, Inc.*(1)		28,540		308,232
Intra-Cellular Therapies, Inc.*		5,336		329,978
Ionis Pharmaceuticals, Inc.*(1)		8,418		348,758
Ironwood Pharmaceuticals, Inc.*		31,097		344,866
Kiniksa Pharmaceuticals Ltd. Class A*		20,851		392,833
Legend Biotech Corp.*(2)		4,982		376,241
Lexicon Pharmaceuticals, Inc.*		137,450		276,275
Ligand Pharmaceuticals, Inc.*		4,405		294,827
Mirum Pharmaceuticals, Inc.*		12,129		312,443
Moderna, Inc.*		2,726		320,741
Neurocrine Biosciences, Inc.*		3,647		371,593
Omniab, Inc. - $12.50 Earnout*(3)		1,295		0
Omniab, Inc. - $15.00 Earnout*(3)		1,295		0
PTC Therapeutics, Inc.*		7,989		322,276
Reata Pharmaceuticals, Inc. Class A*(1)		3,362		556,680
Regeneron Pharmaceuticals, Inc.*		446		330,892
Rhythm Pharmaceuticals, Inc.*(1)		19,414		346,346
Roivant Sciences Ltd.*		35,389		423,960
Sage Therapeutics, Inc.*		5,920		205,306
Sarepta Therapeutics, Inc.*		2,635		285,608
Theravance Biopharma, Inc.*		33,009		326,459
Travere Therapeutics, Inc.*		20,309		349,112
Ultragenyx Pharmaceutical, Inc.*		6,860		295,803
United Therapeutics Corp.*		1,519		368,692
Vanda Pharmaceuticals, Inc.*		54,805		316,773
Vertex Pharmaceuticals, Inc.*		1,008		355,159
Zai Lab Ltd. (China)*(2)		12,423		373,435
TOTAL INVESTMENTS - 99.3%
(Cost $18,544,895)				19,125,952
Other Assets in Excess of Liabilities - 0.7%				134,316
Net Assets - 100.0%			$	19,260,268

*	Non-income producing security.
(1)	All or a portion of the security was on loan. The aggregate market value of securities on loan was $2,660,200; total market value of collateral held by the Fund was $2,726,660. Market value of the collateral held includes non-cash U.S. Treasury securities having a value of $2,726,660.
(2)	American Depositary Receipts.
(3)	Security valued at fair value as determined in good faith by or under the direction of the Trustees. This security is disclosed as a Level 2 security in the Fair Value Hierarchy table located after the Schedule of Investments.

Schedule of Investments - Virtus LifeSci Biotech Products ETF (continued)

July 31, 2023 (unaudited)

Fair Value Measurements

The Fund utilizes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 includes unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access. Level 2 includes observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data. Level 3 includes unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available; representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following table summarizes valuation of the Fund’s investments under the fair value hierarchy levels as of July 31, 2023.

	Level 1		Level 2		Level 3		Total
Asset Valuation Inputs
Common Stocks	$	19,125,952	$	0	$	—	$	19,125,952
Total	$	19,125,952	$	0	$	—	$	19,125,952